

**JONATHAN MCGOEY PHARMACY LIMITED
ACCOUNTS 2025**

**JONATHAN MCGOEY PHARMACY LIMITED
REPORTS AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025**

JONATHAN MCGOEY PHARMACY LIMITED

COMPANY INFORMATION

DIRECTORS Jonathan McGoey
Georgina McGoey

COMPANY SECRETARY Jonathan McGoey

REGISTERED NUMBER 453947

REGISTERED OFFICE 66 Market Street
Ardee
Co. Louth
A92K443

INDEPENDENT AUDITOR OSK Audit Limited
East Point Plaza
East Point
Dublin 3

BANKERS Bank of Ireland
Ardee
Co. Louth

JONATHAN MCGOEY PHARMACY LIMITED

CONTENTS

	Page
Special auditor's report	1 - 4
Abridged statement of financial position	5 - 6
Notes to the abridged financial statements	7 - 13

JONATHAN MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF JONATHAN MCGOEY PHARMACY LIMITED

PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014

-

On 8 December 2025 we reported as auditor of Jonathan McGoey Pharmacy Limited to the directors of the company on the abridged financial statements for the year ended 31 October 2025 on pages 5 to 13 and our report was as follows:

We have examined:

- (i) the abridged financial statements for the year ended 31 October 2025 on pages 5 to 13 which the directors of Jonathan McGoey Pharmacy Limited propose to annex to the Annual return of the company; and
- (ii) the financial statements to be laid before the Annual general meeting which form the basis for those abridged financial statements.

RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITOR

It is your responsibility to prepare the abridged financial statements which comply with the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under Section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to Section 353 of that Act (exemptions available for small companies) and to report our opinion to you.

This report is made solely to the directors in accordance with Section 356 of the Companies Act 2014. Our work was undertaken so that we might state to the directors those matters we are required to state to them in our report under Section 356 of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

BASIS OF OPINION

We have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to annex abridged financial statements to the Annual return of the company and that the abridged financial statements are properly prepared. The scope of our work for the purpose of this report did not include examining or dealing with events after the date of our report on the full financial statements.

OPINION ON FINANCIAL STATEMENTS

In our opinion the directors are entitled under Section 352 of the Companies Act 2014 to annex to the Annual return of the company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of Section 353 of that Act (exemptions available for small sized companies).

OTHER INFORMATION

On 8 December 2025 we reported as auditor of Jonathan McGoey Pharmacy Limited to the members on the company's financial statements for the year ended 31 October 2025 to be laid before its Annual general meeting and our report was as follows:

"We have audited the financial statements of Jonathan McGoey Pharmacy Limited (the 'company') for the year ended 31 October 2025, which comprise the Statement of financial position and the notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued in the United Kingdom by the Financial Reporting Council.

JONATHAN MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF JONATHAN MCGOEY PHARMACY LIMITED (CONTINUED) **PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 October 2025 and of its loss for the year then ended;
- have been properly prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the provisions available for small entities, in the circumstances set out in note 13 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

JONATHAN MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF JONATHAN MCGOEY PHARMACY LIMITED (CONTINUED) **PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

OTHER INFORMATION

The directors are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON THE OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

MATTERS ON WHICH I AM REQUIRED TO REPORT BY EXCEPTION

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the company. We have nothing to report in this regard.

RESPECTIVE RESPONSIBILITIES AND RESTRICTIONS ON USE

RESPONSIBILITIES OF DIRECTORS

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

JONATHAN MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF JONATHAN MCGOEY PHARMACY LIMITED (CONTINUED)
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: <http://www.iaasa.ie>. This description forms part of our Auditor's report."

THE PURPOSE OF OUR AUDIT WORK AND TO WHOM WE OWE OUR RESPONSIBILITIES

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Dylan Byrne
for and on behalf of
OSK Audit Limited
Statutory Audit Firm
East Point Plaza
East Point
Dublin 3

8 December 2025

JONATHAN MCGOEY PHARMACY LIMITED

-

ABRIDGED STATEMENT OF FINANCIAL POSITION
AS AT 31 OCTOBER 2025

	Note	2025 €	2024 €
<u>Fixed assets</u>			
Tangible assets	4	27,558	50,047
Financial asset	5	3,490,083	3,490,083
Investment Property	6	500,190	500,190
		<u>4,017,831</u>	<u>4,040,320</u>
<u>Current assets</u>			
Debtors: amounts falling due within one year	7	488	343
Cash at bank and in hand		744,944	729,052
		<u>745,432</u>	<u>729,395</u>
Creditors: amounts falling due within one year	8	(4,064,558)	(4,063,466)
		<u>(3,319,126)</u>	<u>(3,334,071)</u>
<u>Net current liabilities</u>			
		<u>(3,319,126)</u>	<u>(3,334,071)</u>
<u>Total assets less current liabilities</u>			
		<u>698,705</u>	<u>706,249</u>
<u>Provisions for liabilities</u>			
Deferred tax		(13,628)	(11,753)
		<u>(13,628)</u>	<u>(11,753)</u>
<u>Net assets</u>			
		<u>685,077</u>	<u>694,496</u>
<u>Capital and reserves</u>			
Called up share capital presented as equity		100	100
Other reserves	10	764,344	764,344
Profit and loss account	10	(79,367)	(69,948)
		<u>685,077</u>	<u>694,496</u>
<u>Shareholders' funds</u>			
		<u>685,077</u>	<u>694,496</u>

JONATHAN MCGOEY PHARMACY LIMITED

-

ABRIDGED STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 OCTOBER 2025

These financial statements have been prepared in accordance with the small companies regime.

We, as directors of Jonathan McGoey Pharmacy Limited, state that:

The company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the company has done so on the grounds that it is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:

Jonathan McGoey
Director

Georgina McGoey
Director

Date: 8 December 2025

The notes on pages 7 to 13 form part of these financial statements.

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS **FOR THE YEAR ENDED 31 OCTOBER 2025**

1. GENERAL INFORMATION

These financial statements comprising the Statement of income and retained earnings, the Statement of financial position and the related notes constitute the individual financial statements of Jonathan McGoey Pharmacy Limited for the financial year ended 31 October 2025.

Jonathan McGoey Pharmacy Limited is a private company limited by shares, incorporated in the Republic of Ireland. The Registered Office is at 66 Market Street, Ardee, Co. Louth. The principal place of business is the same as above. The nature of the company's operations and its principal activities are set out in the Directors Report.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied is the Companies Act 2014 and FRS 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland.

The following principal accounting policies have been applied:

2.2 REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

2.3 INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2. ACCOUNTING POLICIES (CONTINUED)

2.4 CURRENT AND DEFERRED TAXATION

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

2.5 Consolidated accounts

The company and its subsidiaries combined meet the size exemption criteria for a group and the company is therefore exempt from the requirement to prepare consolidated financial statements by virtue of meeting the requirements in Section 293(1A) of the Companies Act 2014. Consequently, these financial statements deal with the results of the company as a single entity.

2.6 TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures & fittings	-	20%
---------------------	---	-----

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS **FOR THE YEAR ENDED 31 OCTOBER 2025**

2. ACCOUNTING POLICIES (CONTINUED)

2.7 INVESTMENT PROPERTY

Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.

2.8 VALUATION OF INVESTMENTS

Investments in subsidiaries are measured at cost less accumulated impairment.

2.9 DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.10 CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.11 CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.12 PROVISIONS FOR LIABILITIES

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.

Increases in provisions are generally charged as an expense to profit or loss.

3. EMPLOYEES

The average monthly number of employees, including the directors, during the year was as follows:

	2025	<i>2024</i>
	No.	<i>No.</i>
Directors	2	<i>2</i>

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

4. TANGIBLE FIXED ASSETS

	Fixtures & fittings €
Cost or valuation	
At 1 November 2024	112,444
At 31 October 2025	112,444
Depreciation	
At 1 November 2024	62,397
Charge for the year on owned assets	22,489
At 31 October 2025	84,886
Net book value	
At 31 October 2025	27,558
<i>At 31 October 2024</i>	50,047

5. FINANCIAL ASSETS INVESTMENTS

	Investments in subsidiary undertaking €
Cost or valuation	
At 1 November 2024	3,490,083
At 31 October 2025	3,490,083

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

6. INVESTMENT PROPERTY

	Investment property €
Valuation	
At 1 November 2024	500,190
At 31 October 2025	<u>500,190</u>

The 2025 valuations were made by the Directors, on an open market value for existing use basis.

7. DEBTORS

	2025 €	2024 €
Other debtors	205	60
Prepayments	283	283
	<u>488</u>	<u>343</u>

8. CREDITORS: Amounts falling due within one year

	2025 €	2024 €
Amounts owed to group undertaking	4,063,328	4,062,236
Accruals	1,230	1,230
	<u>4,064,558</u>	<u>4,063,466</u>

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025

9. DEFERRED TAXATION

	2025 €
At beginning of year	(11,753)
Utilised in year	(1,875)
At end of year	(13,628)

The provision for deferred taxation is made up as follows:

	2025 €	2024 €
Accelerated capital allowances	(13,699)	(11,676)
Other differences	71	(77)
	(13,628)	(11,753)

10. RESERVES

Other reserves

Other reserves represents a capital contribution received from its subsidiary undertaking, Donal McGoey Pharmacy Limited.

Profit & loss account

The profit and loss account represents cumulative gains and losses recognised in the profit and loss account.

11. APPROPRIATION OF PROFIT & LOSS ACCOUNT

	2025 €	2024 €
Profit and loss account brought forward at the beginning of the year	(69,948)	(47,840)
Other movement in the profit and loss account	(9,419)	(22,108)
Profit and loss account carried forward at the end of the year	(79,367)	(69,948)

JONATHAN MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025

12. RELATED PARTY TRANSACTIONS

Jonathan McGoey Pharmacy Limited is the parent company of Donal McGoey Pharmacy Limited. Jonathan McGoey Pharmacy Limited owes Donal McGoey Pharmacy Limited €4,063,328 (2024 - €4,062,236) at the year end.

During the year the Director of the company Jonathan McGoey rented a property owned by the company for a market rent of €21,600. No amounts were outstanding at the year end

13. PROVISION AVAILABLE FOR SMALL ENTITIES

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the revenue and assist with the preparation of the financial statements.

14. POST BALANCE SHEET EVENTS

There has been no significant events affecting the company since the year-end.

15. APPROVAL OF FINANCIAL STATEMENTS

The board of directors approved these financial statements for issue on 8 December 2025